Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
Status:
Not yet recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic
prostate cancer experiencing prostate specific antigen (PSA) only progression (without
visceral, bone or lymph node progression) while on abiraterone therapy.